Nuvalent Raises $300M in Public Stock Offering
Originally Published 2 years ago — by Endpoints News
Cancer biotech company Nuvalent has announced a $300 million public offering of its common stock following positive Phase I results for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients, with a 39% objective response rate observed in evaluable patients.